

Emcure Pharmaceuticals Achieves Robust Q4FY25 Performance with 19% Revenue Growth and 63% Profit After Tax Growth

- Revenue from operations at Rs 2,116Cr, up 19.5% YoY
- EBITDA margins at 18.4% with EBITDA up 25.2% YoY
- PAT at 197Cr, up 63.0% YoY
- Domestic business sales at 929Cr, up 24.8% YoY
- International business sales at 1,187Cr, up 15.6% YoY
- The Board has proposed a final dividend of Rs 3/- per share

Pune, May 22, 2025: Emcure Pharmaceuticals (BSE:544210, NSE: EMCURE) today announced its consolidated financial results for the quarter and year ended March 31st, 2025.

The quarter saw strong performance across both our Domestic and International businesses. Emcure's Domestic business grew by 24.8% YoY led by our Women's Health and Cardio franchises and further aided by our new focus areas of Dermatology and OTC. The International business registered a growth of 15.6% led by a robust 39.3% growth in the Rest of the World segment. Our Canada business continues to perform well with Mantra now fully integrated. In Europe we recently acquired a portfolio of products and secured key regulatory approvals which will aid growth going forward.

Commenting on the results, Satish Mehta, CEO and Managing Director, Emcure Pharmaceuticals Ltd., said, "Emcure delivered a very strong performance in Q4 with all our businesses segments contributing to growth. Over the past year we have effectively executed our strategies across both Domestic and International markets. On the Domestic side we have expanded our covered market and built a strong product pipeline of upcoming launches. In the International markets we are seeing approvals for our differentiated product offerings. Moving forward, while we continue to drive growth, our key priorities will be improving margins through new product launches and operating efficiencies."

Revenue break-up:

Rs Cr	4Q25	4Q24	YOY%	3Q25	QOQ%	FY25	FY24	YOY%
Revenue from operations	2,116	1,771	19.5%	1,963	7.8%	7,896	6,658	18.6%
Domestic	929	744	24.8%	888	4.5%	3,660	3,144	16.4%
International	1,187	1,027	15.6%	1,075	10.5%	4,236	3,514	20.5%
EM	481	345	39.3%	365	31.6%	1,510	1,180	27.9%
EU	396	389	1.7%	358	10.6%	1,474	1,411	4.4%
CA	310	293	6.2%	352	-11.5%	1,252	923	35.7%

Contd.

Performance Summary (Consolidated)

Rs Cr	4Q25	4Q24	YOY%	3Q25	QOQ%	FY25	FY24	YOY%
Revenue from operations	2,116	1,771	19.5%	1,963	7.8%	7,896	6,658	18.6%
Material Cost	892	671	33.0%	783	14.0%	3,147	2,475	27.1%
Gross Profit	1,224	1,100	11.2%	1,180	3.7%	4,749	4,183	13.5%
<i>Gross Profit Margins</i>	<i>57.8%</i>	<i>62.1%</i>		<i>60.1%</i>		<i>60.1%</i>	<i>62.8%</i>	
Employee Costs	373	339	10.3%	367	1.8%	1,446	1,292	11.9%
Other expenses	461	450	2.3%	451	2.1%	1,834	1,661	10.4%
EBITDA	390	311	25.2%	362	7.8%	1,469	1,230	19.4%
<i>EBITDA Margins</i>	<i>18.4%</i>	<i>17.6%</i>		<i>18.4%</i>		<i>18.6%</i>	<i>18.5%</i>	
Other Income	4	12		4		67	43	
Depreciation and Amortisation	97	91		97		384	312	
Finance Costs inc. Forex	26	65		39		171	224	
Exceptional Items	10	0		0		10	10	
Profit Before Tax (PBT)	261	167	56.1%	230	13.3%	971	727	33.6%
Tax	64	46		74		264	199	
Profit After Tax (PAT)	197	121	63.0%	156	26.4%	707	528	34.1%
<i>PAT Margins</i>	<i>9.3%</i>	<i>6.8%</i>		<i>8.0%</i>		<i>9.0%</i>	<i>7.9%</i>	

About Emcure Pharmaceuticals Ltd:

Emcure Pharmaceuticals Ltd. (EPL) is a leading Indian pharma company headquartered in Pune engaged in developing, manufacturing and globally marketing a broad range of pharmaceutical products. Known for its commitment to innovation, quality, and patient-centricity, Emcure is an R&D driven company that develops and manufactures a wide range of differentiated pharmaceutical products designed to improve patient health and well-being across several major therapeutic areas. Established in 1981, EPL is ranked as the 12th largest pharma company in India in terms of Domestic Sales for MAT June 2024. Emcure is present in 70+ countries globally including Europe and Canada.

Contact:

Media

corpcomm@emcure.com

Investor Relations

investor.relations@emcure.com

Details of the Earnings Call:

- **Date:** Thursday, May 22, 2025
- **Time:** 3:30 p.m. – 4:30 p.m. (IST)
- **Dial-In Numbers:**
 - Universal Access: [+91 22 6280 1220](tel:+912262801220) / [+91 22 7115 8122](tel:+912271158122)
 - USA: 1 866 746 2133
 - UK: 0 808 101 1573
 - Singapore: 800 101 2045
 - Hong Kong: 800 964 448